Decision Resources Group anticipates the next ten years to be an exciting time in the type 1 diabetes (T1D) space as the number of treatment options continues to grow. Existing agents fail to…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who the…
Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative market for pharmacotherapies owing to the lack of approved agents and the disease’s prevalence. The body of…
DRG Epidemiology's coverage of glioma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the incidence of glioma for each country, as well…
Pharmacotherapy for adult asthma has two main goals: address underlying airway inflammation and promote bronchodilation. Two types of therapy are used to achieve these goals—maintenance therapy (…
The accelerated approvals of Kymriah (Novartis) for the treatment of children oryoung adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite Pharma, a Gilead…
MARKET OUTLOOK Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus, eczema, and, in some cases, disrupted sleep and poor quality of life. Topical agents (e.g.,…
Hydroxychloroquine, corticosteroids, and conventional immunosuppressants are the mainstay of treatment for systemic lupus erythematosus (SLE), a chronic, complex autoimmune disease affecting…
Metformin and the sulfonylureas are the most heavily prescribed drugs in T2D and dominate the early lines of therapy prior to disease progression, which requires insulin replacement. The emergence…
MARKET OUTLOOK Conventional therapies (5-ASAs, corticosteroids) are typically used to treat mild to moderate pediatric ulcerative colitis (UC), whereas tumor necrosis factor-alpha (TNF-α)…
Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA) and the only other oral targeted therapy besides Celgene’s PDE-4 inhibitor, Otezla, approved for this indication…
Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA) and the only other oral targeted therapy besides Celgene’s PDE-4 inhibitor, Otezla, approved for this indication…
Allergic rhinitis is a chronic immunoglobulin E-mediated respiratory response to environmental allergens. It is typically treated with intranasal corticosteroids, followed by antihistamines, mast…
With the launch of four adalimumab biosimilars into the European market in October 2018—Amgevita (Amgen), Imraldi (Biogen), Hulio (Mylan), and Hyrimoz (Sandoz)—competition within the already…
Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the United States. Its launch comes years after that of Pfizer’s Jak inhibitor, Xeljanz (…
